

GENERAL ANNOUNCEMENT::ANNOUNCEMENT PURSUANT TO RULE 706A OF THE CATALIST RULES

Issuer & Securities

Issuer/ Manager

SINGAPORE PAINCARE HOLDINGS LIMITED

Securities

SINGAPORE PAINCARE HOLDINGS LIMITED - SGXE51400773 - FRQ

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date & Time of Broadcast

14-Feb-2025 18:06:52

Status

New

Announcement Sub Title

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE CATALIST RULES

Announcement Reference

SG250214OTHRNRK4

Submitted By (Co./ Ind. Name)

Dr. Lee Mun Kam Bernard

Designation

Chairman and Chief Executive Officer

Description (Please provide a detailed description of the event in the box below)

Please refer to the attachment.

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "Sponsor") in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.

Attachments

[SPCH-LR706A.pdf](#)

Total size =252K MB

SINGAPORE PAINCARE HOLDINGS LIMITED

Company Registration No.:201843233N
(Incorporated in the Republic of Singapore)

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE CATALIST RULES

The Board of Directors ("**Board**") of Singapore Paincare Holdings Limited (the "**Company**") and together with its subsidiaries, the "**Group**") wishes to announce the following transaction that occurred during the six-month financial period from 1 July 2024 to 31 December 2024, pursuant to Rule 706A of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist:-

A. Disposal of AE MEDICAL FERNVALE PTE LTD - a 100% owned subsidiary

The Company had on 16 September 2024 entered into a sale and purchase agreement (the "**SPA**") with Mustard Seed Health Pte. Ltd. (the "**Purchaser**") for the sale by the Company of its entire shareholdings in AE Medical Fernvale Pte. Ltd. ("**AE Fernvale**").

The rationale of the sale is to monetise a long-term asset, streamline the Group's businesses for better utilisation of available resources and to redeploy its resources towards opportunities that will enhance shareholders' value.

The aggregate consideration for the sale was S\$829,000 in cash which was received on completion (the "**Consideration**"). The Consideration was arrived at on a willing-buyer willing-seller basis, after negotiations which were conducted on an arm's length basis between the Purchaser and the Company. The net asset value of AE Fernvale for the audited financial year ended 30 June 2024 was S\$116,287.

By Order of the Board

Lee Mun Kam Bernard
Executive Chairman and Chief Executive Officer
14 February 2025

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**") in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.